Клинико-функциональное течение хронической обструктивной болезни легких в сочетании с ишемической болезнью сердца на фоне комплексной терапии с применением крестора

The article shows the results of prospective research of clinical and functional course of chronic obstructive pulmonary disease combined with ischemic heart disease in 39 patients. The standard therapy of 21 patients was supplemented with Crestor® (rosuvastatin calcium), the inhibitor of HMG-CoA-reductase of the fourth generation and the therapy of 17 patients did not include Сrestor®. The observations were made throughout the year. It was found out that the combination of crestor with the standard therapy of chronic obstructive pulmonary disease and ischemic heart disease contributes to the control over the symptoms of the combined pathology (it decreases the intensity of short breath, sputum production, the frequency and intensity of the cough, the frequency of angina attacks) and 1.9 times reduces the frequency of exacerbations and the severity of comorbid pathology. Long application of Crestor® combined with the standard therapy leads to the increase of FEV1 by 7.04±1.86%, FEV1/FVC by 7.16±1.62% and to the decrease of arterial stiffness and the activity of laboratory parameters of the systemic inflammation. The research proves the significant anti-inflammatory effect of Crestor® and the feasibility of its application while treating chronic obstructive pulmonary disease.